{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390282679847344896.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.2169/internalmedicine.50.5971"}},{"identifier":{"@type":"URI","@value":"http://www.jstage.jst.go.jp/article/internalmedicine/50/21/50_21_2503/_pdf"}},{"identifier":{"@type":"NAID","@value":"130001288604"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2012323356"}}],"dc:title":[{"@language":"en","@value":"Antithrombotic Drug Therapy for IgA Nephropathy: A Meta Analysis of Randomized Controlled Trials"}],"dc:language":"en","description":[{"type":"abstract","notation":[{"@language":"en","@value":"<b>Background</b> Antithrombotic agents, including antiplatelet agents, anticoagulants and thrombolysis agents, have been widely used in the management of immunoglobulin A (IgA) nephropathy in Chinese and Japanese populations. To systematically evaluate the effects of antithrombotic agents for IgA nephropathy.<br> <b>Methods</b> Data sources consisted of MEDLINE, EMBASE, the Cochrane Library, Chinese Biomedical Literature Database (CBM), Chinese Science and Technology Periodicals Databases (CNKI) and Japana Centra Revuo Medicina (http://www.jamas.gr.jp) up to April 5, 2011. The quality of the studies was evaluated from the intention to treat analysis and allocation concealment, as well as by the Jadad method. Meta-analyses were performed on the outcomes of proteinuria and renal function.<br> <b>Results</b> Six articles met the predetermined inclusion criteria. Antithrombotic agents showed statistically significant effects on proteinuria (p<0.0001) but not on the protection of renal function (p=0.07). The pooled risk ratio for proteinuria was 0.53, [95% confidence intervals (CI): 0.41-0.68; I<sup>2</sup>=0%] and for renal function it was 0.42 (95% CI 0.17-1.06; I<sup>2</sup>=72%). Subgroup analysis showed that dipyridamole was beneficial for proteinuria (p=0.0003) but had no significant effects on protecting renal function. Urokinase had statistically significant effects both on the reduction of proteinuria (p=0.0005) and protecting renal function (p<0.00001) when compared with the control group.<br> <b>Conclusion</b> Antithrombotic agents had statistically significant effects on the reduction of proteinuria but not on the protection of renal function in patients with IgAN. Urokinase had statistically significant effects both on the reduction of proteinuria and on protecting renal function. Urokinase was shown to be a promising medication and should be investigated further.<br>"}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410282679847344901","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021715592"}],"foaf:name":[{"@language":"en","@value":"Liu Xiu-Juan"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Division of Nephrology, 94 Hospital of Chinese PLA, PR China"},{"@language":"en","@value":"Division of Nephrology, Kidney Institute and Key Lab of Chinese People's Liberation Army (PLA), General Hospital of Chinese PLA, Postgraduate Medical College of Chinese PLA, PR China"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679847344897","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021715594"}],"foaf:name":[{"@language":"en","@value":"Geng Yan-Qiu"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Division of Nephrology, Kidney Institute and Key Lab of Chinese People's Liberation Army (PLA), General Hospital of Chinese PLA, Postgraduate Medical College of Chinese PLA, PR China"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679847344896","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021715596"}],"foaf:name":[{"@language":"en","@value":"Xin Shao-Nan"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Nanchang Military Academy of Chinese PLA, PR China"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679847344898","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021715597"}],"foaf:name":[{"@language":"en","@value":"Huang Guo-Ming"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Division of Nephrology, 94 Hospital of Chinese PLA, PR China"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679847344902","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021715600"}],"foaf:name":[{"@language":"en","@value":"Tu Xiao-Wen"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Division of Nephrology, 94 Hospital of Chinese PLA, PR China"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679847344900","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021715602"}],"foaf:name":[{"@language":"en","@value":"Ding Zhong-Ru"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Division of Nephrology, 94 Hospital of Chinese PLA, PR China"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679847344899","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021715604"}],"foaf:name":[{"@language":"en","@value":"Chen Xiang-Mei"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Division of Nephrology, Kidney Institute and Key Lab of Chinese People's Liberation Army (PLA), General Hospital of Chinese PLA, Postgraduate Medical College of Chinese PLA, PR China"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09182918"},{"@type":"EISSN","@value":"13497235"}],"prism:publicationName":[{"@language":"en","@value":"Internal Medicine"},{"@language":"en","@value":"Intern. Med."}],"dc:publisher":[{"@language":"en","@value":"The Japanese Society of Internal Medicine"},{"@language":"ja","@value":"一般社団法人 日本内科学会"}],"prism:publicationDate":"2011","prism:volume":"50","prism:number":"21","prism:startingPage":"2503","prism:endingPage":"2510"},"reviewed":"false","url":[{"@id":"http://www.jstage.jst.go.jp/article/internalmedicine/50/21/50_21_2503/_pdf"},{"@id":"https://search.jamas.or.jp/link/ui/2012323356"}],"availableAt":"2011","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Glomerulonephritis","dc:title":"Glomerulonephritis"},{"@id":"https://cir.nii.ac.jp/all?q=IgA%20nephropathy","dc:title":"IgA nephropathy"},{"@id":"https://cir.nii.ac.jp/all?q=Antithrombotic%20agents","dc:title":"Antithrombotic agents"},{"@id":"https://cir.nii.ac.jp/all?q=Meta%20analysis","dc:title":"Meta analysis"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360292619099445888","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of Dipyridamole on the Short-Term Evolution of Glomerulonephritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620988712704","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Three‐year randomized controlled trial of dipyridamole and low‐dose warfarin in patients with IgA nephropathy and renal impairment"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094962096256","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"META‐ANALYSIS OF MYCOPHENOLATE MOFETIL IN IgA NEPHROPATHY"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569305836160","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Management of IgA nephropathy: Evidence-based recommendations"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569521532416","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Glomerular fibrin deposition and removal"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570679025024","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of co-administration of urokinase and benazepril on severe IgA nephropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044255355264","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Dipyridamole Specifically Decreases Platelet-Derived Growth Factor Release from Platelets"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044826936320","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Is the Antiproteinuric Effect of Dipyridamole Hemodynamically Mediated?"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044979772800","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Controlled Trial of Antiplatelet Agents in Mesangial IgA Glomerulonephritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520356033280","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Immunosuppressive agents for treating IgA nephropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699996268524672","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Immunoglobulin a nephropathy with mild renal lesions: a call in the forest for physicians and nephrologists"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699996404698752","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Controlled Trial of Combined Therapy for Newly Diagnosed Severe Childhood IgA Nephropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944389160320","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effect of Dilazep Hydrochloride, an Antiplatelet Agent, on the Proliferation of Cultured Mouse Glomerular Mesangial Cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944949041152","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"IgA Nephropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262946234706560","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"An “evidence-based” survey of therapeutic options for IgA nephropathy: assessment and criticism"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893644920320","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Fish oil therapy for IgA nephropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825896319847296","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Immunomodulation with Low-Dose Immunoglobulins for Moderate IgA Nephropathy and Henoch-Schönlein Purpura"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369432189568","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"What is meant by intention to treat analysis? Survey of published randomised controlled trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370267880576","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107371268368896","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Immunosuppressive treatments for immunoglobulin A nephropathy: A meta‐analysis of randomized controlled trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320905161728","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"In vivo desensitization of glycogenolysis to Ca2+-mobilizing hormones in rat liver cells."}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794420627456","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"IgA Nephropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268806431744","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?"}]},{"@id":"https://cir.nii.ac.jp/crid/2051151842048569216","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical guidelines for immunoglobulin A (IgA) nephropathy in Japan, second version"}]},{"@id":"https://cir.nii.ac.jp/crid/2051151842048827904","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Meta-analysis of antiplatelet therapy for IgA nephropathy"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:0038093817"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.50.5971"},{"@type":"CIA","@value":"130001288604"}]}